25E-NBOMe

Coronary artery disease, Uncontrolled hypertension, Arrhythmias, Structural heart disease

The NBOMe class produces a consistent sympathomimetic toxidrome comprising tachycardia, hypertension, and vasoconstriction. Pre-existing cardiovascular conditions significantly increase the risk of acute cardiovascular crisis. Class-level case series document hypertensive emergencies and cardiac arrest.

Epilepsy, History of seizures, Seizure predisposition

Seizures are a well-documented complication of NBOMe toxicity across the class. Individuals with pre-existing seizure disorders face compounded risk. Class-level data show seizures occurring even in individuals without seizure history.

Schizophrenia, Schizoaffective disorder

As a full agonist at 5-HT₂A receptors with subnanomolar-to-low-nanomolar potency, 25E-NBOMe carries a high risk of precipitating psychotic episodes in individuals with psychotic spectrum disorders. The NBOMe class is associated with psychosis-like states even in individuals without psychiatric history.

Bipolar I disorder, Bipolar II disorder

Manic episode precipitation is a theoretical risk with potent 5-HT₂A agonists in individuals with bipolar spectrum disorders. No substance-specific or class-specific case reports exist for NBOMe-precipitated mania, but the risk is inferred from the broader psychedelic class.

Panic disorder, Severe generalized anxiety disorder

The NBOMe class is associated with anxiety, panic attacks, and acute psychological distress at higher doses. Individuals with pre-existing severe anxiety disorders face heightened vulnerability to these adverse psychological effects.

Hepatic insufficiency, Cirrhosis, Severe liver disease

25E-NBOMe undergoes extensive Phase I hepatic metabolism with 26 metabolites identified in human liver microsomes (Grafinger et al. 2018). Impaired liver function could reduce clearance, prolong exposure, and increase toxicity risk. The severity of this effect has not been characterized.

Pregnancy, Planned pregnancy

Preclinical data reviewed by Herian & Świt (2023) show that 25X-NBOMe compounds cause developmental impairments in animal models. No human gestational exposure data exist, but the preclinical signal combined with the compound's potent pharmacological activity makes pregnancy an absolute contraindication.

SSRI therapy, SNRI therapy

Concurrent use of SSRIs or SNRIs with a potent 5-HT₂A full agonist carries a theoretical risk of serotonin syndrome. The severity of this interaction has not been characterized for any NBOMe compound specifically.

MAOI therapy (phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide)

Co-administration of 25E-NBOMe with any monoamine oxidase inhibitor creates a theoretical risk of serotonin syndrome via combined serotonergic excess. No specific interaction data exist, but the mechanism-based risk is considered serious given 25E-NBOMe's full agonism at 5-HT₂A/2C.

Lithium therapy

Lithium is anecdotally associated with increased seizure risk when combined with serotonergic psychedelics. Given that NBOMe compounds independently lower the seizure threshold, this combination carries compounded seizure risk. No controlled data exist for any NBOMe + lithium combination.